Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling. Its clinical trials evaluate the treatment of chronic inflammatory respiratory diseases including severe asthma, CRSwNP, and COPD.
6 investors
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology. It serves healthcare providers using proprietary laboratory technology and AI/ML analytical tools for genomic testing and personalized medicine.
6 investors
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.
6 investors
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
6 investors
VitalBio develops the VitalOne, a diagnostic device that delivers comprehensive lab-grade blood test results in minutes from a small blood sample, using robotics, biochemistry, computer vision, and microfluidics. It targets healthcare providers and patients seeking point-of-care diagnostic testing.
6 investors
Cultivated animal products company.
6 investors
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis. Its pipeline is built on technologies licensed from FIMA at the University of Navarra in Spain.
6 investors
Waypoint Bio uses artificial intelligence, computer vision, and pooled screening to conduct deep phenotyping across thousands of cell therapy designs, enabling the discovery and optimization of superior cell therapy candidates for development.
6 investors
Weave Bio offers an AI-native regulatory platform for preparing and managing eCTD-formatted regulatory dossiers, automating data organization, authoring, review, publishing and response management across the therapeutic lifecycle. It serves biotech and pharma companies as well as CROs and consultants in the drug development and regulatory submission space.
6 investors
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.
6 investors
Windfall Bio develops microbial-based solutions that convert methane into valuable products for industrial and agricultural customers. The company uses naturally occurring microorganisms to enable commercial-scale methane mitigation across industries.
6 investors
YourChoice Therapeutics is developing YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials. The company targets male contraceptive users seeking alternatives to condoms or vasectomy.
6 investors
Zafrens develops a unified drug discovery platform that integrates isolation, imaging, and sequencing workflows to accelerate the identification of therapeutic compounds across modalities. The platform leverages AI and high-resolution data to compress timelines in drug development.
6 investors
J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.
6 investors
Oxford Cancer Analytics develops a diagnostics platform that combines reproducible proteomic measurement with AI to produce evidence-based insights supporting clinical decision-making. Its focus is on lung disease, beginning with Chronic Obstructive Pulmonary Disease (COPD) and extending to conditions such as lung cancer.
5 investors
STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells. The platform enables in vivo genetic medicines with an initial focus on rare hematological diseases and CAR-T therapies, supporting approaches such as gene editing, RNA therapeutics, and immune cell engineering.
5 investors
4baseCare develops AI-powered precision oncology tools that combine genomic data, clinical history, and real-world evidence to support cancer treatment decisions, molecular tumor board collaboration, biomarker discovery, and clinical trial design. It offers tumor DNA/RNA profiling, liquid biopsy (ctDNA), combined tissue-liquid-germline testing, HRD assays, and hereditary cancer testing, with initiatives serving cancer patients in India.
5 investors
64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.
5 investors
A-Alpha Bio uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical discovery and development. The company operates experimental (AlphaSeq) and computational (AlphaBind) platforms to accelerate the design of novel therapeutics.
5 investors
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch. It develops drug candidates like ABS-201 for conditions including androgenetic alopecia and applies reverse immunology for novel target discovery.
5 investors
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients. It operates in oncology-focused drug discovery and development.
5 investors
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
5 investors
Adaptyv Bio develops technologies for protein engineering that enable the design and testing of new proteins for applications in medicine, industrial enzymes, and functional materials. The company serves protein engineers and researchers developing therapeutic and industrial biological products.
5 investors
Adimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners. It offers services from antigen acquisition through preclinical lead generation, including AI-guided protein engineering, and works with partners through discovery, platform licensing, and technology-module collaboration models.
5 investors